Article PDF
References
Hoogenboom, H.R., Marks, J.D., Griffiths, A.D. & Winter, G. Building antibodies from their genes. Immunol. Rev. 130, 41–68 (1992).
Evans, R.W. et al. Immunosuppressive therapy as a determinant of transplantation outcomes. Transplantation 55, 1297–1305 (1993).
Tcheng, J.E. et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 90, 1757–1764 (1994).
Neal, C.E. & Meis, L.C. Correlative imaging with monoclonal antibodies in colorectal, ovarian, and prostate cancer. Semin. nucl. Med. 24, 272–285 (1994).
Winter, G., Griffiths, A.D., Hawkins, R.E. & Hoogenboom, H.R. Making antibodies by phage display technology. Annu. Rev. Immun. 12, 433–455 (1994).
Pietersz, G.A. & Krauer, K. Antibody-targeted drugs for the therapy of cancer. J. Drug Targeting 2, 183–215 (1994).
Holliger, P., Prospero, T. & Winter, G. “Diabodies”: Small bivalent and bispecific antibody fragments. Proc. natn. Acad. Sci. U.S.A. 90, 6444–6448 (1993).
Janda, K.D., Lo, C.H., Li, T., Barbas, C.F., Wirsching, P. & Lerner, R.A. Direct selection for a catalytic mechanism from combinatcjrial antibody libraries. Proc. natn. Acad. Sci. U.S.A. 91, 2532–2536 (1994).
Burton, D.R. & Barbas, C.F. Human antibodies from combinatorial libraries. Adv. Immun. 57, 191–280 (1994).
Lonberg, N. et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368, 856–859 (1994).
Green, L.L. et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nature Genet. 7, 13–21 (1994).
Muller-Eberhard, H.J. Molecular organization and function of the complement system. Annu. Rev. Biochem. 57, 321–347 (1988).
Nicholson-Weller, A. & Halperin, J.A. Membrane signaling by complement C5b-9, the membrane attack complex. Immun. Res. 12, 244–257 (1993).
Morgan, B.P. Clinical complementology: recent progress and future trends. Eur. J. clin. Invest. 24, 219–228 (1994).
Jiang, H., Burdick, D., Glabe, C.G., Cotman, C.W. & Tenner, A.J. Beta amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immun. 152, 5050–5059 (1994).
Wang, Y., Rollins, S.A., Madri, J.A. & Matis, L.A. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. natn. Acad. Sci. U.S.A. (in the press).
Rinder, C.S. et al. A monoclonal antibody directed at the human C5 component of complement serves as a potent inhibitor of leukocyte and platelet activation during simulated extracorporeal circulation. J. clin. Invest. (in the press).
Evans, M.J. et al. In vivo and in vitro inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Molec. Immun. (in the press).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Matis, L., Rollins, S. Complement-specific antibodies: Designing novel anti-inflammatories. Nat Med 1, 839–842 (1995). https://doi.org/10.1038/nm0895-839
Issue Date:
DOI: https://doi.org/10.1038/nm0895-839
This article is cited by
-
Complement-targeted therapy: development of C5- and C5a-targeted inhibition
Inflammation and Regeneration (2016)
-
Humoral-Targeted Immunotherapies in Multiple Sclerosis
Neurotherapeutics (2013)
-
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
Nature Biotechnology (2007)
-
Eculizumab
Nature Reviews Drug Discovery (2007)
-
New therapies in development for autoimmune diseases: their rationale for combination treatment
Springer Seminars in Immunopathology (2001)